MINUTES

PCF OVERSIGHT BOARD

May 7, 2020

ZOOM TELECONFERENCE

Dr. Christopher Foret, Chairman, convened the meeting of the Patient's Compensation Fund Oversight Board at 5:30 PM on Thursday, May 7, 2020.

The following Board members were in attendance:

Dr. Christopher Foret, Chairman Dr. Luis Alvarado Mr. Marcus Naquin Mr. Kent Guidry Mr. Gregory Waddell Mr. Robert Ruel

Dr. Patrick Breaux

The following Board members were absent:

Dr. Corey Hebert Ms. Jennifer DeCuir

Others present:

Mr. Ken Schnauder Ms. Betty Patrick Mr. Larry Warren Mr. Dave Woolridge Ms. Barbara Woodard Mr. Jeff Williams Mr. Kurt Loup Mr. Matt Padberg Dr. J. Michael Conerly

Mr. Kirk Groh Ms. Shelly Fowler

Dr. Foret called the meeting to order and asked that the record reflect seven Board members were in attendance and a quorum was present. Dr. Foret then welcomed the guests to the meeting and asked all present to introduce themselves.

Dr. Foret called for approval of the April 16, 2020 minutes. Dr. Breaux moved for the minutes to be adopted and Mr. Naquin seconded the motion; by verbal vote, the minutes were adopted with no dissenting votes.

Dr. Foret called for the quarterly investment update. Mr. Matt Padberg of Cardinal Investment Advisors presented the Board with a detailed quarterly report and portfolio update. Mr. Padberg advised the portfolio underperformed for the first quarter of the year; however, it did improve significantly during the month of April. He advised the portfolio has outperformed its overall benchmark over the year. Mr. Padberg stated there is no way to know what effect the current pandemic of COVID-19 will have on the stock market in the near future but he is very comfortable with the portfolio. He asked the Board given the recent crisis and market fluctuations whether they were comfortable with the current portfolio structure and they confirmed they were happy with the portfolio.

Dr. Foret called for discussion and approval of the FY 2020-21 administrative contracts. Mr. Schnauder presented a list of agency contracts requiring Board approval to be effective July 1, 2020 through June 30, 2021. He advised these were the same contracts approved by the Board PCFOB Minutes May 7, 2020

the prior fiscal year, and the contracts are renewed annually. After some discussion, Mr. Naquin moved for the renewal contracts to be approved and Dr. Alvarado seconded the motion; by verbal vote, the motion for renewal of the contracts was adopted with no dissenting votes.

Dr. Foret asked for the financial and budget reports. Ms. Woodard informed the Board the Fund balance for the fiscal year to date was approximately \$1,141,095,051, the total net collected in surcharge payments to date was approximately \$130,449,103 and the total net filing fees collected to date were \$234,295. She advised the investment income through March was approximately \$38,794,794, the total operating expenses to date were \$4,927,794, and the claims expenses to date were \$128,354,649.

Mr. Schnauder then discussed the first quarter comparison report and advised all categories were in line except claims which had increased 11% from 2019. He advised the claims budget even with the Board-approved increase in March would be exhausted before the June 30 fiscal year end; he will discuss the need for a possible increase at the June 2020 meeting. There were no questions asked and no public comments made.

Dr. Foret called for the claims report. Mr. Loup informed the Board for the month of April there were 60 panels filed, 97 panels closed, 81 claims opened, and 88 claims closed, ending the month with a total, pending claims count of 4,272. Mr. Loup advised \$0 in judicial interest was paid for the month and \$71,182 in legal fees and expenses were paid. Mr. Loup presented 43 claims for settlement approval for the month in the amount of \$19,256,116. There were no questions asked and no public comments made.

Dr. Foret thanked the guests for attending the meeting. Dr. Breaux then made a motion for the Board to move into Executive Session; Mr. Guidry seconded the motion. The verbal vote was unanimous, and the Board moved into Executive Session to discuss matters of litigation.

June 4, 2020		

Dr. Christopher Foret, Chairman

Date